Health Catalyst Inc (HCAT) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 35% of 52W Range • RSI-14 at 46.8 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±11.2% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While HCAT currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Technology with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.72) and Max Pain ($1.88) forces dealer call-delta covering toward $3.53.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Health Catalyst Inc (HCAT) slipped -0.56% to $1.79, trading at 35% of its 52-week range ($0.96 – $3.36). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the
SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, will release
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +1.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HCAT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HCAT. Explore sector supply chains on /butterfly.
Across 714 tracked Technology securities in the Roarable RQD universe, Health Catalyst Inc (HCAT) ranks #622 by composite RQD confidence (35/100, grade D-) and #505 by equity capitalization ($134.7M). Within this direct 5-issuer industry benchmark cohort, HCAT leads on earnings valuation at N/A trailing P/E, while DOYU leads on capital efficiency and profitability with 1.6% ROIC and 12.8% gross margin. DSC currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with HCAT at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HCAT
ACTIVE
Health Catalyst Inc | D- | 35/100 | — | — | -35.0% | -0.56% | $134.7M | Benchmark Subject |
| SANG Sangoma Technologies Corporation | C- | 60/100 | — | — | — | +1.07% | $157.9M | /sang-vs-hcat → |
| DOYU DouYu International Holdings Limited ADS | D- | 36/100 | — | 12.8% | 1.6% | -0.55% | $110.2M | /doyu-vs-hcat → |
| DSC DSC Holdings Ltd. | C | 62/100 | — | — | — | +4.53% | $184.8M | /dsc-vs-hcat → |
| PODC PodcastOne Inc. | D+ | 55/100 | — | — | -16.9% | +5.71% | $78.4M | /podc-vs-hcat → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Health Catalyst Inc (HCAT) reported GAAP revenue of $311.1M (+1.5% vs. FY2024 revenue of $306.6M , and +5.1% cumulative change since FY2023) , GAAP net income of -$178.0M, operating cash flow of $731.0K, and free cash flow of -$237.0K (-101.8% YoY). On the balance sheet, HCAT closed FY2025 with $502.6M in total assets against $151.6M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $311.1M | -$178.0M | $731.0K | -$237.0K | $502.6M | $151.6M |
| FY2024 (FY) | 2024-12-31 | $306.6M | -$69.5M | $14.6M | $12.9M | $858.9M | $151.2M |
| FY2023 (FY) | 2023-12-31 | $295.9M | -$118.1M | -$33.1M | -$33.1M | — | — |
As of 2026-11-01, Health Catalyst Inc (NASDAQ: HCAT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.79 (-0.56% 1D, market cap $134.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 714 tracked Technology issuers, HCAT ranks #622 in composite RQD confidence.
Within the Technology sector (Computer Software: Programming Data Processing), HCAT carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SANG (Sangoma Technologies Corporation) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $157.9M) and DOYU (DouYu International Holdings Limited ADS) posts a D- grade (36/100 RQD, P/E N/A, ROIC 1.6%, cap $110.2M). Among the 5-stock peer group, HCAT leads on earnings multiple (N/A) while DOYU leads on capital efficiency (1.6% ROIC).
Per HCAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001636422), Health Catalyst Inc generated $311.1M in revenue (+1.5% YoY), -$178.0M in net income, and -$237.0K in free cash flow against $502.6M in total assets and $151.6M in total debt. Key quantitative strengths: Established market leader in Technology with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
HCAT last traded at $1.79 (-0.56% on volume of 282,318 shares), positioning the stock +4.07% above its 50-day simple moving average ($1.72) and +4.07% above its 200-day simple moving average ($1.72). Across its 52-week range of $0.96 to $3.36, HCAT sits at the 34.6% percentile with a 14-day RSI of 46.8 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($1.59 to $1.99).
Why HCAT Stock slipped -0.56% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.